MHRA Opens Consultation on Indefinite CE Mark Recognition

Why It Matters

Indefinite CE recognition offers manufacturers regulatory certainty and cost savings, while maintaining patient safety through enhanced post‑market oversight. The shift also signals the UK’s strategic focus on MedTech innovation and market stability.

Key Takeaways

• 90% of GB devices currently CE‑marked.
• Indefinite CE recognition reduces dual‑regulatory costs.
• UKCA mark shifts to innovative, AI‑driven devices.
• Higher‑risk CE devices face international reliance oversight.
• Consultation closes 10 April 2026.

Pulse Analysis

Post‑Brexit, the United Kingdom has operated two parallel medical‑device regimes: the legacy CE system and the newer UKCA mark. The split has created compliance complexity for manufacturers seeking access to both EU and GB markets, prompting industry calls for clearer guidance. By proposing indefinite recognition of EU‑MDR and IVDR‑compliant devices, the MHRA aims to harmonise regulatory expectations, reduce duplicated testing, and prevent supply disruptions that could arise from divergent timelines. This approach mirrors broader government efforts to streamline trade‑related standards across sectors.

For MedTech firms, the proposal translates into tangible financial and operational benefits. Eliminating a fixed expiry for CE marks means manufacturers can avoid the costly process of re‑certifying products under UKCA, especially for legacy devices that dominate the market. The dual‑track model preserves the UKCA pathway for breakthrough innovations—particularly AI‑driven diagnostics—allowing companies to showcase cutting‑edge solutions without sacrificing the stability of established product lines. The targeted international reliance route for higher‑risk devices adds a layer of scrutiny while still facilitating market entry, balancing safety with commercial agility.

Patient safety remains central to the MHRA’s agenda. Strengthening post‑market surveillance and fostering information‑sharing with EU regulators ensures that indefinite CE recognition does not dilute oversight. Aligning the initiative with the Life Sciences Sector Plan underscores the UK’s ambition to become a global MedTech hub by 2030. As stakeholders submit feedback ahead of the April 2026 deadline, the outcome will shape the regulatory landscape, influencing investment decisions, supply‑chain resilience, and the pace of innovation across the British healthcare system.